David Jackson

In 1999 global pharmaceutical and healthcare company Bristol-Myers Squibb and the BMS Foundation made what to this day is the largest corporate commitment to fight HIV/Aids in Africa. This came through the launch of Secure the Future: Care and Support for Women and Children with HIV/Aids. The programme is a $150-million investment, with projects in 12 African countries.

Responding effectively to the HIV/Aids and tuberculosis epidemics is a challenge for companies such as gold producer AngloGold Ashanti for business and moral reasons. The burden of both diseases in the local mining industry is high. Similarly, the high incidence of malaria in the company’s Africa operations calls for effective interventions.

A multifaceted international partnership programme to combat the growing multidrug-resistant tuberculosis (MDR-TB) pandemic is well underway, with a five-year project strategy until the end of 2011 also being developed within South Africa. In 2003, global pharmaceutical giant Lilly launched the Lilly Multidrug-Resistant Tuberculosis Partnership project.